Amgen, Bind Partner To Develop Targeted Nanomedicine For Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen will develop a targeted cancer medicine using a novel Accurin from Bind’s nanomedicine platform and one of its proprietary kinase inhibitors; the deal represents the first major partnership applying a nanomedicine technology to a molecularly targeted drug.